Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy

Journal of Clinical Oncology

Volumn 19, Issue 4, 2001, Pages 1183-1194

  Schilder, R J ^a   Gallo, J M ^a   Millenson, M M ^a   Bookman, M A ^a   Weiner, L M ^a   Rogatko, A ^a   Rogers, B ^a   Padavic Shallers, K ^a   Boente, M ^a   Rosenblum, N ^a   Adams, A L ^a   Ciccotto, S ^a   Ozols, R F ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; OVARY CANCER; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SMALL CELL CARCINOMA; SOLID TUMOR; STOMATITIS; TREATMENT OUTCOME;

EID: 0035865306     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.4.1183     Document Type: Article

References (57)

1. Taxol: The first of the taxanes, an important new class of antitumor agents
2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
3. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group
4. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO/PAC) in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 158)
5. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynäekologische Onkologie (AGO) study group trial
6. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis
7. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC)
8. Clinical status and optimal use of topotecan
9. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
10. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-level phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
11. Inhibition of removal of cisplatin-induced interstrand crosslinks by topotecan
12. Phase I/II study of topotecan + cisplatin in patients with non-small cell lung cancer (NSCLC)
13. Phase I study of topotecan and cisplatin in patients with advanced malignancy: A CALGB study
14. Sequences of topotecan and cisplatin: Phase I, pharmacologic and in vitro studies examining sequence-dependence
15. A phase I trial of fixed systemic exposure (AUC) of carboplatin (CARBO) with continuous infusion (CI) topotecan (TOPO) in pediatric solid tumors
16. A phase I trial and pharmacologic trial of sequences in paclitaxel and topotecan in previously treated ovarian epithelial malignancies
17. Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin on sub- and postconfluent tumor cell cultures
18. Evaluation of 9-dimethylaminomethyl-10 hydroxycamptothecin against xenografts derived front adult and childhood solid tumors
19. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors
20. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor
21. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor
22. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
23. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial
24. Lack of efficacy of 24-hour infusional topotecan in recurrent (platinum sensitive) ovarian cancer (ROC)
25. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells
26. A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer
27. Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer
28. A phase I study of topotecan (T), cisplatin (C) and paclitaxel (P) in newly diagnosed epithelial ovarian cancer, a Gynecologic Oncology Group (GOG 9602) study
29. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer
30. Phase I study of topotecan plus carboplatin/paclitaxel in advanced solid tumors
31. Phase I trial of topotecan, paclitaxel, and carboplatin in patients with advanced refractory malignancies
32. A phase I trial of topotecan, paclitaxel, and carboplatin with or without growth factor support
33. Phase I combination chemotherapy of weekly topotecan (T), paclitaxel (P), and carboplatin (C) in patients with advanced cancer
34. Phase I/II study or topotecan (T), paclitaxel (P), and carboplatin (C) with G-CSF in metastatic and recurrence head and neck cancer
35. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support tor ovarian and small-cell lung cancer patients: A dose-finding study
36. Phase I trial of paclitaxel, topotecan and cisplatin in adult patients with advanced malignancies
37. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions
38. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
39. Creatinine clearance bedside estimate
40. Cancer phase I clinical trials: Efficient dose escalation with overdose control
41. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir
42. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma
43. NCOMP: A Windows-based computer program for noncompartmental analysis of pharmacokinetic data
44. Optimum numerical integration methods for estimation of area-under-the-curve (AUC) and area-under-the-moment-curve (ALIMC)
45. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel
46. 2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer
47. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients
48. Low-level taxane exposure increases the activity of topoisomerase I targeted agents
49. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion
50. Synergism between cisplatin and topoisomerase I inhibitors. NB-506 and SN- 38, in human small cell lung cancer cells
51. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro
52. Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design
53. Clinical pharmacokinetics of topotecan
54. Phase I and pharmacodynamic study of Taxol in refractory adult acute leukemias
55. Phase I trial of Taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma
56. High-dose chemotherapy and autologous bone marrow transplantation compared with MA-COP-B in aggressive B-cell lymphoma